tbuckley/cabot-search huggingface dataset:
A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction
Authors: Ni Xia, Yuzhi Lu, Muyang Gu, Nana Li, Meilin Liu, Jiao Jiao, Zhengfeng Zhu, Jingyong Li, Dan Li, Tingting Tang, Bingjie Lv, Shaofang Nie, Min Zhang, Mengyang Liao, Yuhua Liao, Xiangping Yang, Xiang Cheng
Journal: Circulation (2020)

Regulatory T cells (Tregs), traditionally recognized as potent suppressors of immune response, are increasingly attracting attention because of a second major function: residing in parenchymal tissues and maintaining local homeostasis. However, the existence, unique phenotype, and function of so-called tissue Tregs in the heart remain unclear.In mouse models of myocardial infarction (MI), myocardial ischemia/reperfusion injury, or cardiac cryoinjury, the dynamic accumulation of Tregs in the injured myocardium was monitored. The bulk RNA sequencing was performed to analyze the transcriptomic characteristics of Tregs from the injured myocardium after MI or ischemia/reperfusion injury. Photoconversion, parabiosis, single-cell T-cell receptor sequencing, and adoptive transfer were applied to determine the source of heart Tregs. The involvement of the interleukin-33/suppression of tumorigenicity 2 axis and Sparc (secreted acidic cysteine-rich glycoprotein), a molecule upregulated in heart Tregs, was further evaluated in functional assays.We showed that Tregs were highly enriched in the myocardium of MI, ischemia/reperfusion injury, and cryoinjury mice. Transcriptomic data revealed that Tregs isolated from the injured hearts had plenty of differentially expressed transcripts in comparison with their lymphoid counterparts, including heart-draining lymphoid nodes, with a phenotype of promoting infarct repair, indicating a unique characteristic. The heart Tregs were accumulated mainly because of recruitment from the circulating Treg pool, whereas local proliferation also contributed to their expansion. Moreover, a remarkable case of repeatedly detected T-cell receptor of heart Tregs, more than that of spleen Tregs, suggests a model of clonal expansion. Besides, HelioshighNrp-1high phenotype proved the mainly thymic origin of heart Tregs, with a small contribution of phenotypic conversion of conventional CD4+ T cells, proved by the analysis of T-cell receptor repertoires and conventional CD4+ T cells adoptive transfer experiments. The interleukin-33/suppression of tumorigenicity 2 axis was essential for sustaining heart Treg populations. Last, we demonstrated that Sparc, which was highly expressed by heart Tregs, acted as a critical factor to protect the heart against MI by increasing collagen content and boosting maturation in the infarct zone.We identified and characterized a phenotypically and functionally unique population of heart Tregs that may lay the foundation to harness Tregs for cardioprotection in MI and other cardiac diseases.
1760P COVID-19 severe pneumonia in cancer patients: Impact and predictive factors
Authors: P. Peinado, E. Sanz Garcia, I. Moreno, M. Dorta, B. Alvarez, R. Alvarez Gallego, R. Madurga, L. Ugidos, J. Rodriguez Pascual, C. Muñoz, E. Garcia-Rico, A. Cubillo
Journal: Annals of Oncology (2020)
Machine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individuals
Authors: Fátima Sánchez-Cabo, Xavier Rossello, Valentín Fuster, Fernando Benito, Jose Pedro Manzano, Juan Carlos Silla, Juan Miguel Fernández-Alvira, Belén Oliva, Leticia Fernández-Friera, Beatriz López-Melgar, José María Mendiguren, Javier Sanz, Jose María Ordovás, Vicente Andrés, Antonio Fernández-Ortiz, Héctor Bueno, Borja Ibáñez, José Manuel García-Ruiz, Enrique Lara-Pezzi
Journal: Journal of the American College of Cardiology (2020)

Clinical practice guidelines recommend assessment of subclinical atherosclerosis using imaging techniques in individuals with intermediate atherosclerotic cardiovascular risk according to standard risk prediction tools.The purpose of this study was to develop a machine-learning model based on routine, quantitative, and easily measured variables to predict the presence and extent of subclinical atherosclerosis (SA) in young, asymptomatic individuals. The risk of having SA estimated by this model could be used to refine risk estimation and optimize the use of imaging for risk assessment.The Elastic Net (EN) model was built to predict SA extent, defined by a combined metric of the coronary artery calcification score and 2-dimensional vascular ultrasound. The performance of the model for the prediction of SA extension and progression was compared with traditional risk scores of cardiovascular disease (CVD). An external independent cohort was used for validation.EN-PESA (Progression of Early Subclinical Atherosclerosis) yielded a c-statistic of 0.88 for the prediction of generalized subclinical atherosclerosis. Moreover, EN-PESA was found to be a predictor of 3-year progression independent of the baseline extension of SA. EN-PESA assigned an intermediate to high cardiovascular risk to 40.1% (n = 1,411) of the PESA individuals, a significantly larger number than atherosclerotic CVD (n = 267) and SCORE (Systematic Coronary Risk Evaluation) (n = 507) risk scores. In total, 86.8% of the individuals with an increased risk based on EN-PESA presented signs of SA at baseline or a significant progression of SA over 3 years.The EN-PESA model uses age, systolic blood pressure, and 10 commonly used blood/urine tests and dietary intake values to identify young, asymptomatic individuals with an increased risk of CVD based on their extension and progression of SA. These individuals are likely to benefit from imaging tests or pharmacological treatment. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).
1508P Safety, efficacy, and patients' satisfaction of initial peripherally inserted central catheters compared with usual intravenous access in terminally ill cancer patients: A randomized phase II study
Authors: K. Park, J.-J. Kim, S-B. Oh, K.S. Jung, S.Y. Oh, E-J. Park, Y.J. Hong, J.H. Kim, J.Y. Jang, U-B. Jeon
Journal: Annals of Oncology (2020)
802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
Authors: M. Brunelli, S. Buti, S.E. Rebuzzi, M. Milella, V. Vellone, M. Bersanelli, M. Maruzzo, U. Basso, A. Signori, V. Martelli, F. Catalano, A. Damassi, V. Murianni, S. Merler, C. Casartelli, G. Fornarini
Journal: Annals of Oncology (2020)
1640P Pegylated liposomal doxorubicin (PLD) as first line treatment in AIDS-related Kaposi’s sarcoma (AIDS-KS): A single institution retrospective study
Authors: D. Dalu, M.S. Cona, D. De Francesco, L. Ammoni, S. Rota, C. Fasola, A. Foschi, N.M. La Verde
Journal: Annals of Oncology (2020)
769P APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma
Authors: D. Natesan, L. Zhang, H. Martell, P. Devine, B. Stohr, J. Grenert, J. Van Ziffle, N. Joseph, B.C. Bastian, S. Umetsu, C. Onodera, E. Chan, A. Desai, S. Porten, J. Chou, T. Friedlander, L. Fong, E.J. Small, A. Sweet-Cordero, V.S. Koshkin
Journal: Annals of Oncology (2020)
1426P Gender differences in treatment characteristics and outcomes of esophagogastric cancer surgery - Data from the Dutch upper-GI cancer audit
Authors: M.C. Kalff, A.D. Wagner, R.H. Verhoeven, V.E.P.P. Lemmens, H.W.M. van Laarhoven, S.S. Gisbertz, M.I. van Berge Henegouwen
Journal: Annals of Oncology (2020)
1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience
Authors: R. Lobefaro, G. Viscardi, R. Di Liello, G. Massa, M.L. Iacovino, F. Sparano, C.M. Della Corte, R. Ferrara, D. Signorelli, C. Proto, A. Prelaj, G. Galli, A. De Toma, M. Brambilla, M. Ganzinelli, B. Trevisan, F.G.M. De Braud, F. Morgillo, M.C. Garassino, G. Lo Russo
Journal: Annals of Oncology (2020)
1533P Real-life data from the platform for outcome, quality of life and translational research on pancreatic cancer - PARAGON
Authors: S-E. Al-Batran, W. Blau, R. Liersch, S. Mahlmann, A. Lueck, D. Pink, M. Wolf, L. Scheuer, B. Zäpf, F. Mueller-Braun, C. Pauligk, T. Habibzade, R.D. Hofheinz, T.O. Götze
Journal: Annals of Oncology (2020)
163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)
Authors: H. Bando, N. Masuda, T. Yamanaka, T. Kadoya, M. Takahashi, S. Nagai, S. Ohtani, T. Aruga, E. Suzuki, Y. Kikawa, H. Yasojima, H. Kasai, H. Ishiguro, H. Kawabata, S. Morita, H. Haga, T.R. Kataoka, R. Uozumi, S. Ohno, M. Toi
Journal: Annals of Oncology (2020)
1469P The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
Authors: J.P. Hall, K. Khela, R. Moon, C. Middleton-Dalby, D. Bertwistle, H. Xiao
Journal: Annals of Oncology (2020)
572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials
Authors: O. Saavedra Santa Gadea, A. Hernando-Calvo, R. Berché, I. Matos, I. Gardeazabal, A.B. Azaro Pedrazzoli, M. Vieito Villar, I. Braña, G. Alonso Casal, V. Galvao de Aguiar, A. Pedrola, G. Argiles Martinez, T. Macarulla Mercadé, J. Capdevila, S. Cedres, A. Oaknin, E. Elez, J. Tabernero, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2020)
1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
Authors: N.M.J. Van Den Heuvel, I.L.M. Reijers, J.M. Versluis, E.A. Rozeman, K. Jóźwiak, K.H. Blommers, R.P.M. Saw, K.P.M. Suijkerbuijk, E. Kapiteijn, A.A.M. Van der Veldt, G.A.P. Hospers, A.J. Spillane, T. Pennington, M. Wouters, A.M. Menzies, A.C.J. van Akkooi, L. van de Poll-Franse, G.V. Long, C.U. Blank, A.H. Boekhout
Journal: Annals of Oncology (2020)
1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey
Authors: M. Tagliamento, F. Spagnolo, F. Poggio, D. Soldato, B. Conte, T. Ruelle, E. Barisione, A. De Maria, L. Del Mastro, M. Di Maio, M. Lambertini
Journal: Annals of Oncology (2020)
International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E<sub>2</sub>Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions
Authors: Xavier Norel, Yukihiko Sugimoto, Gulsev Ozen, Heba Abdelazeem, Yasmine Amgoud, Amel Bouhadoun, Wesam Bassiouni, Marie Goepp, Salma Mani, Hasanga D. Manikpurage, Amira Senbel, Dan Longrois, Akos Heinemann, Chengcan Yao, Lucie H. Clapp
Journal: Pharmacological Reviews (2020)

Prostaglandins are derived from arachidonic acid metabolism through cyclooxygenase activities. Among prostaglandins (PGs), prostacyclin (PGI<sub>2</sub>) and PGE<sub>2</sub> are strongly involved in the regulation of homeostasis and main physiologic functions. In addition, the synthesis of these two prostaglandins is significantly increased during inflammation. PGI<sub>2</sub> and PGE<sub>2</sub> exert their biologic actions by binding to their respective receptors, namely prostacyclin receptor (IP) and prostaglandin E<sub>2</sub> receptor (EP) 1–4, which belong to the family of G-protein–coupled receptors. IP and EP1–4 receptors are widely distributed in the body and thus play various physiologic and pathophysiologic roles. In this review, we discuss the recent advances in studies using pharmacological approaches, genetically modified animals, and genome-wide association studies regarding the roles of IP and EP1–4 receptors in the immune, cardiovascular, nervous, gastrointestinal, respiratory, genitourinary, and musculoskeletal systems. In particular, we highlight similarities and differences between human and rodents in terms of the specific roles of IP and EP1–4 receptors and their downstream signaling pathways, functions, and activities for each biologic system. We also highlight the potential novel therapeutic benefit of targeting IP and EP1–4 receptors in several diseases based on the scientific advances, animal models, and human studies. <h3>SIGNIFICANCE STATEMENT</h3> In this review, we present an update of the pathophysiologic role of the prostacyclin receptor, prostaglandin E<sub>2</sub> receptor (EP) 1, EP2, EP3, and EP4 receptors when activated by the two main prostaglandins, namely prostacyclin and prostaglandin E<sub>2</sub>, produced during inflammatory conditions in human and rodents. In addition, this comparison of the published results in each tissue and/or pathology should facilitate the choice of the most appropriate model for the future studies.
713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214
Authors: M. Regan, O.A. Jegede, C. Mantia, T. Powles, L. Werner, S. Huo, V. Del Tejo, B. Stwalley, M.B. Atkins, D.F. McDermott
Journal: Annals of Oncology (2020)
1995P Clinical significance of cannabinoid receptor CB2 expression in non-small cell lung cancer (NSCLC)
Authors: N.G. Tsoukalas, C. Giaginis, P. Alexandrou, M. Liontos, M. Tolia, M. Kiakou, I. Sfiniadakis, N. Kavantzas, E. Patsouris, S. Theocharis
Journal: Annals of Oncology (2020)
Administering gender: Trans men’s sexual and reproductive challenges in Argentina
Authors: Andrés Mendieta, Salvador Vidal-Ortiz
Journal: International Journal of Transgender Health (2020)

There is dearth of experiential information about transgender men's sexual and reproductive rights needs and challenges in Argentina, a country that passed the first, and then most comprehensive, Gender Identity Law. Local rules, and administrative, social service, and medical policies fail to meet the transformative scope of the law, thus, creating a tension between trans identity recognition, and medical services.This study aimed to illustrate Argentinean trans men's challenges with the medical and healthcare system, when seeking to become pregnant, in prenatal care, or when needing an abortion.This study sought to counter exploitative research engagement on potentially vulnerable populations. It did so through examining newspaper coverage of trans men's self-representation. Following online media searches, the authors identified three trans men's public narratives about accessing medical services. The authors utilized thematic analysis to develop themes based on the men's accounts of experiences related to administrative violence.Themes developed focused on (mis)gendering by medical staff, either inadvertently or intentionally, as well as the layers of institutional violence lived by the trans men vis a vis the laws and public policies already in place.The paper closes by discussing implications for clinical services. It seeks to question implementations that center cisgender experiences, in order to take into account other identities, bodies and experiences.
1894P Final results from a prospective study examining exhaled breath alcohol levels following weekly paclitaxel chemotherapy
Authors: R.J. Keogh, M. Milewski, K. Browne, K. Egan, M. Hennessy, Z. Coyne, D. Cowzer, A. Linehan, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach
Journal: Annals of Oncology (2020)
1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Authors: V. Calvo, E. Carcereny Costa, M. Guirado, A.L. Ortega Granados, R. Lopez Castro, D. Rodriguez-Abreu, R. Garcia Campelo, E. del Barco Morillo, O. Juan-Vidal, C.J. Camps, J.L. Gonzalez-Larriba, M. Domine Gomez, J.M. Trigo Perez, M. Cobo Dols, S. Cerezo Gonzalez, J. Calzas Rodriguez, B. Massuti Sureda, J. Bosch-Barrera, T. Moran, M. Provencio Pulla
Journal: Annals of Oncology (2020)
1292P Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib
Authors: A.R. Minchom, D.S.W. Tan, E. Massarelli, V. Subbiah, V. Boni, B. Robinson, L.J. Wirth, L.M. Hess, X. Huang, J.F. Kherani, E. Olek, C. McCoach
Journal: Annals of Oncology (2020)
485P Link between PODXL and the EGFR axis in metastatic colorectal cancer and in vitro: Implications for improved treatment stratification
Authors: C. Siesing, A. Larsson, A. Petersson, B. Nodin, H. Sorbye, K. Aasebo, C. Qvortrup, P. Pfeiffer, F. Pontén, B. Glimelius, J. Eberhard, K. Jirström, E. Karnevi
Journal: Annals of Oncology (2020)
17P Engineering and expression of constitutive activators of the PD-1 and LAG-3 signaling pathways
Authors: L. Chocarro, M.J. García Granda, M. Zuazo, H. Arasanz, A. Bocanegra, E. Blanco, C. Hernández Sáez, G. Fernández Hinojal, R. Vera, G. Kochan, D. Escors
Journal: Annals of Oncology (2020)
LBA73 The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01
Authors: P. Kvistborg, A. Gangaev, S. Ketelaars, S. Patiweal, A. Dopler, O. Isaeva, K. Hoefakker, S. De Biasi, C. Mussini, G. Guaraldi, M. Girardis, C. Talavera Ormeno, P. Hekking, N. Lardy, M. Toebes, R. Balderas, T.N. Schumacher, H. Ovaa, A. Cossarizza
Journal: Annals of Oncology (2020)
Arterial Stiffness Preceding Diabetes
Authors: Mengyi Zheng, Xinyuan Zhang, Shuohua Chen, Yongjian Song, Quanhui Zhao, Xiang Gao, Shouling Wu
Journal: Circulation Research (2020)

Previous studies on the relationship between diabetes and arterial stiffness were mostly cross-sectional. A few longitudinal studies focused on one single direction. Whether the association between arterial stiffness and diabetes is bidirectional remains unclear to date.To explore the temporal relationship between arterial stiffness and fasting blood glucose (FBG) status.Included were 14 159 participants of the Kailuan study with assessment of brachial-ankle pulse wave velocity (baPWV) from 2010 to 2015, and free of diabetes, cardiovascular and cerebrovascular diseases, and chronic kidney disease at baseline. FBG and baPWV were repeatedly measured at baseline and follow-ups. Cox proportional hazard regression model was used to estimate hazard ratios and 95% confidence intervals (CIs) of incident diabetes across baseline baPWV groups: <1400 cm/s (ref), 1400≤ baPWV <1800 cm/s, and ≥1800 cm/s. Path analysis was used to analyze the possible temporal causal relationship between baPWV and FBG, among 8956 participants with repeated assessment of baPWV and FBG twice in 2010 to 2017. The mean baseline age of the observed population was 48.3±12.0 years. During mean 3.72 years of follow-up, 979 incident diabetes cases were identified. After adjusting for potential confounders, the hazard ratio (95% CI) for risk of diabetes was 1.59 (1.34-1.88) for the borderline arterial stiffness group and 2.11 (1.71-2.61) for the elevated arterial stiffness group, compared with the normal ideal arterial stiffness group. In the path analysis, baseline baPWV was associated with follow-up FBG (the standard regression coefficient was 0.09 [95% CI, 0.05-0.10]). In contrast, the standard regression coefficient of baseline FBG for follow-up baPWV (β=0.00 [95% CI, -0.02 to 0.02]) was not significant.Arterial stiffness, as measured by baPWV, was associated with risk of developing diabetes. Arterial stiffness appeared to precede the increase in FBG.
Covid-19: Government poised to amend regulations to allow use of unlicensed vaccine
Authors: Clare Dyer
Journal: BMJ (2020)

The UK government has set out plans to amend drug regulations in case it decides that covid-19 vaccines should be used before they are licensed, in a bid to roll them out more quickly. 1 In a consultation on the proposals that ran from 28 August to 18 September the Department of Health and Social Care for England explained that if a suitable vaccine emerged with strong evidence of safety, quality, and efficacy the government would seek to license it through the usual route but could supply it in the meantime.
537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
Authors: M. Vieito Villar, A. Spreafico, V. Moreno, I. Braña, T. Hernandez, A. Abdul Razak, J. Wang, N. Haddish-Berhane, J. Mehta, A. Johnson, A. Maes, J. Haslam, P. Mistry, A. Kalota, L. Lenox, J. Infante, M. Lorenzi, H. Xie, J. Lauring, M.R. Patel
Journal: Annals of Oncology (2020)
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Authors: Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa
Journal: BMJ (2020)

To compare the risk of cardiovascular events between sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among people with type 2 diabetes in a real world context of clinical practice.Multi-database retrospective cohort study using a prevalent new user design with subsequent meta-analysis.Canadian Network for Observational Drug Effect Studies (CNODES), with administrative healthcare databases from seven Canadian provinces and the United Kingdom, 2013-18.209 867 new users of a SGLT2 inhibitor matched to 209 867 users of a DPP-4 inhibitor on time conditional propensity score and followed for a mean of 0.9 years.The primary outcome was major adverse cardiovascular events (MACE, a composite of myocardial infarction, ischaemic stroke, or cardiovascular death). Secondary outcomes were the individual components of MACE, heart failure, and all cause mortality. Cox proportional hazards models were used to estimate site specific adjusted hazards ratios and 95% confidence intervals, comparing use of SGLT2 inhibitors with use of DPP-4 inhibitors in an as treated approach. Site specific results were pooled using random effects meta-analysis.Compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with decreased risks of MACE (incidence rate per 1000 person years: 11.4 v 16.5; hazard ratio 0.76, 95% confidence interval 0.69 to 0.84), myocardial infarction (5.1 v 6.4; 0.82, 0.70 to 0.96), cardiovascular death (3.9 v 7.7; 0.60, 0.54 to 0.67), heart failure (3.1 v 7.7; 0.43, 0.37 to 0.51), and all cause mortality (8.7 v 17.3; 0.60, 0.54 to 0.67). SGLT2 inhibitors had more modest benefits for ischaemic stroke (2.6 v 3.5; 0.85, 0.72 to 1.01). Similar benefits for MACE were observed with canagliflozin (0.79, 0.66 to 0.94), dapagliflozin (0.73, 0.63 to 0.85), and empagliflozin (0.77, 0.68 to 0.87).In this large observational study conducted in a real world clinical practice context, the short term use of SGLT2 inhibitors was associated with a decreased risk of cardiovascular events compared with the use of DPP-4 inhibitors.ClinicalTrials.gov NCT03939624.
1638P Are all leiomyosarcomas created equal? Clinical characteristics and experience of a single reference centre
Authors: R. Teres Lleida, B. Martin Cullell, M. Borrell Puy, A. Bujosa Rodríguez, P.G. Gallardo Melo, C. Molto Valiente, M. Riudavets Melia, M. Aguado Sorolla, A. Piedra Cascon, J.C. Tapia, J. Gavira Diaz, R. Orellana Fernandez, S. Bague Rosell, A. Gallardo Alcañiz, A. Lopez-Pousa, P. Cerda Serda, A. Sebio Garcia
Journal: Annals of Oncology (2020)